EXPLORE!

PCSK9 Inhibitors in Diabetic Dyslipidemia

  993 Views

#Diabetes and Endocrinology 

Prof Sudarshan Ramachandran, UK    26 November 2018

  1. Despite recent debate, the evidence for the lipid hypothesis still remains strong.
  2. PCSK9 inhibitors are third-line LDL-C lowering agents in the UK. The efficacy is similar in patients with or without type 2 diabetes. No increase in new-onset diabetes is evident at this point.
  3. The FOURIER and ODYSSEY OUTCOMES randomized controlled studies show-lowering of CVD in keeping with the lipid hypothesis.
  4. Outpatient data shows that similar LDL-C reductions (55%) can be seen with both PCSK9 inhibitors - Evolocumab and alirocumab. Considerable variation exists in the LDL-C reduction (21-83%) in our series.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.